Regeneus agrees to US vet product deal with Lonza

Sydney-based regenerative therapy company Regeneus has announced that its CryoShot Canine product with be manufactured by Lonza in the US.

Sydney-based
regenerative therapy company Regeneus has announced that its CryoShot Canine
product with be manufactured by Lonza for registration in the US.

Regeneus,
which was founded in 2007 and listed on the ASX in September last year, said
that Lonza had experience manufacturing stem cells to US and European
standards.

“We view this as the start of a long-term relationship in
which Lonza will manufacture CryoShot for the world wide canine market,” said head of veterinary health Dr Duncan Thomson in a statement.

“Our clinical trial work in Australia
has been rewarding and it is now time to begin registration of the CryoShot
product in the US and European markets.”

The manufacture of the musculoskeletal treatment products will
take place at Lonza’s Walkersville, Maryland site.

Regeneus’s HiQCell stem cell treatment uses a donor’s own
fat cells and has been used on humans to treat arthritic conditions. Its
CryoShot and AdiCell products treat dogs and horses in a similar way.

“Our primary focus is musculoskeletal ailments, mostly osteoarthritis
and tendinopathy,” Regeneus says on its website.

“Osteoarthritis is a common disease affecting one in five
animals.”

 

Image: dogquality.com